Affini-T Therapeutics

Kim Nguyen, Ph.D., Chief Technical Officer

April 12 | 2:00pm | Dark Horse Consulting Ballroom 

Boston, MA


Affini-T is unlocking the power of T cells and targeting core oncogenic drivers to develop potentially curative therapies for solid tumor cancers. Our differentiated cell therapy platform harnesses state-of-the-art engineering and synthetic biology capabilities to target even the most devastating cancer-driving mutations, beginning with KRAS. We leverage these tools to optimize T cell functions and rewrite the rules of the solid tumor microenvironment, enabling the potential for sustained clinical outcomes in patients. Building on the world-class innovation inherent in our leadership team, founders and technologies, we are powered to develop transformational medicines that last.

By using this website you agree to accept our Privacy Policy and Terms & Conditions